Biofrontera Inc. Warrants

The global photodynamic therapy (PDT) market is expected to grow at a CAGR of 8.3% from 2023 to 2035, driven by minimally invasive treatment demand, expanding applications in oncology and dermatology, and technological innovations. North America is projected to grow at 14% CAGR, while Europe currently holds 50% market share. Over 70 PDT therapies...

Biofrontera Inc., a biopharmaceutical company specializing in photodynamic therapy (PDT), announced it will report Q1 2026 financial results on May 14, 2026, followed by a conference call at 11:00 a.m. ET. The company commercializes Ameluz® with RhodoLED® lamp series for treating actinic keratosis and is conducting clinical trials to expand use...

Biofrontera completed its Phase 1 pharmacokinetic study for Ameluz® to expand treatment of actinic keratoses to neck, trunk, and extremities, with plans to submit a supplemental New Drug Application to the FDA in summer 2026.

Biofrontera reported a 15% revenue increase in Q2 2025, with record Ameluz sales and strategic shifts towards a royalty model. The company is advancing clinical trials for label expansions in actinic keratosis and basal cell carcinoma treatments.

Biofrontera reported Q2 2025 revenues of $9.0 million, a 15% increase from the previous year. The company restructured its relationship with Biofrontera AG, acquiring US intellectual property and securing $11 million in funding. Despite increased legal expenses, the company saw improvements in sales effectiveness and is progressing with clinical ...